Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

    Recruiting

    1 1 1
    Investigated Drugs:
    Belgium France Germany Ireland Italy The Netherlands +3
  • Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    Belgium Germany Romania Spain
  • Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium Bulgaria Czechia France Germany Hungary +6
  • Title: Study of 5-Aminolevulinic Acid for detecting tumor tissue during surgery in patients with ovarian cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Germany
  • Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    France
  • Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

    Recruiting

    3 1 1 1
    Portugal
  • Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Spain
  • Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

    Recruiting

    3 1 1 1
    Czechia France Germany Italy
  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Belgium France Italy Poland Spain
  • Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer

    Recruiting

    1 1 1 1
    France Spain